Keryx's kidney drug meets main goals of mid-stage study

(Reuters) - Keryx Biopharmaceuticals Inc said its kidney drug met the main goals of a mid-stage study in patients with chronic kidney disease who were not on dialysis. Shares of the company rose about 16 percent to $12.84 in premarket trading. The drug showed a statistically significant reduction in serum phosphorus, high levels of which are associated with progression of the disease and increased rate of death, after 12 weeks of treatment compared with a placebo. The trial tested the drug in patients with chronic kidney disease who had iron deficiency anemia and elevated levels of serum phosphorus.



via Health News Headlines - Yahoo! News http://news.yahoo.com/keryxs-kidney-drug-meets-main-goals-mid-stage-130542130--finance.html